EHHADH
Basic information
Region (hg38): 3:185190624-185281990
Previous symbols: [ "ECHD" ]
Links
Phenotypes
GenCC
Source:
- primary Fanconi syndrome (Supportive), mode of inheritance: AD
- Fanconi renotubular syndrome 3 (Limited), mode of inheritance: AD
- Fanconi renotubular syndrome 3 (Limited), mode of inheritance: AD
- Fanconi renotubular syndrome 3 (Limited), mode of inheritance: AD
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Fanconi renotubular syndrome 3 | AD | Renal | Manifestations in the described individuals can include severe rickets, and early knowledge may allow medical/dietary interventions (eg, with calcitriol, and phosphate supplementation) to prevent (and treat) this complication | Renal | 1627757; 24401050 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_provided (115 variants)
- not_specified (100 variants)
- EHHADH-related_disorder (87 variants)
- Fanconi_renotubular_syndrome_3 (18 variants)
- Chronic_kidney_disease (2 variants)
- Fanconi_renotubular_syndrome_1 (1 variants)
- Cholestasis (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the EHHADH gene is commonly pathogenic or not. These statistics are base on transcript: NM_000001966.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 16 | 27 | 46 | |||
| missense | 132 | 24 | 10 | 168 | ||
| nonsense | 9 | |||||
| start loss | 0 | |||||
| frameshift | 10 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 1 | 1 | 166 | 52 | 13 |
Highest pathogenic variant AF is 0.000016727796
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| EHHADH | protein_coding | protein_coding | ENST00000231887 | 7 | 91367 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 5.24e-10 | 0.831 | 125497 | 2 | 248 | 125747 | 0.000995 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | -0.0259 | 394 | 393 | 1.00 | 0.0000204 | 4636 |
| Missense in Polyphen | 139 | 137.71 | 1.0094 | 1666 | ||
| Synonymous | 0.688 | 139 | 150 | 0.928 | 0.00000765 | 1492 |
| Loss of Function | 1.68 | 19 | 28.7 | 0.662 | 0.00000156 | 366 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.00134 | 0.00126 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.000272 | 0.000272 |
| Finnish | 0.000139 | 0.000139 |
| European (Non-Finnish) | 0.00104 | 0.00104 |
| Middle Eastern | 0.000272 | 0.000272 |
| South Asian | 0.00308 | 0.00301 |
| Other | 0.000491 | 0.000489 |
dbNSFP
Source:
- Disease
- DISEASE: Fanconi renotubular syndrome 3 (FRTS3) [MIM:615605]: A disease due to a generalized dysfunction of the proximal kidney tubule resulting in decreased solute and water reabsorption. Patients have polydipsia and polyuria with phosphaturia, glycosuria and aminoaciduria. They may develop hypophosphatemic rickets or osteomalacia, acidosis and a tendency toward dehydration. Some eventually develop renal insufficiency. {ECO:0000269|PubMed:24401050}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Tryptophan metabolism - Homo sapiens (human);Butanoate metabolism - Homo sapiens (human);beta-Alanine metabolism - Homo sapiens (human);Lysine degradation - Homo sapiens (human);Propanoate metabolism - Homo sapiens (human);Peroxisome - Homo sapiens (human);Fatty acid degradation - Homo sapiens (human);PPAR signaling pathway - Homo sapiens (human);Valine, leucine and isoleucine degradation - Homo sapiens (human);Valproic Acid Metabolism Pathway;Constitutive Androstane Receptor Pathway;PPAR Alpha Pathway;Nuclear Receptors Meta-Pathway;Mitochondrial LC-Fatty Acid Beta-Oxidation;Valproic acid pathway;Amino Acid metabolism;PPAR signaling pathway;Liver steatosis AOP;mechanism of gene regulation by peroxisome proliferators via ppara;Butanoate metabolism;fatty acid β-oxidation (unsaturated, odd number);Metabolism of lipids;Metabolism of proteins;Tyrosine metabolism;3-oxo-10R-octadecatrienoate beta-oxidation;Leukotriene metabolism;Omega-3 fatty acid metabolism;Saturated fatty acids beta-oxidation;Trihydroxycoprostanoyl-CoA beta-oxidation;Beta-oxidation of very long chain fatty acids;Peroxisomal lipid metabolism;Metabolism;Lysine degradation;Peroxisomal protein import;Fatty acid metabolism;inactivation of gsk3 by akt causes accumulation of b-catenin in alveolar macrophages;Propanoate metabolism;Mono-unsaturated fatty acid beta-oxidation;Omega-6 fatty acid metabolism;Valine, leucine and isoleucine degradation;Butanoate metabolism;Propanoate metabolism;Bile acid biosynthesis;Dimethyl-branched-chain fatty acid mitochondrial beta-oxidation;Di-unsaturated fatty acid beta-oxidation;Phytanic acid peroxisomal oxidation;Vitamin E metabolism;fatty acid β-oxidation (peroxisome);fatty acid β-oxidation;Tryptophan degradation;Valine Leucine Isoleucine degradation
(Consensus)
Recessive Scores
- pRec
- 0.408
Intolerance Scores
- loftool
- 0.325
- rvis_EVS
- 2.27
- rvis_percentile_EVS
- 98.24
Haploinsufficiency Scores
- pHI
- 0.0627
- hipred
- N
- hipred_score
- 0.230
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.224
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | High |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ehhadh
- Phenotype
- mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype;
Gene ontology
- Biological process
- internal protein amino acid acetylation;protein targeting to peroxisome;fatty acid beta-oxidation;fatty acid beta-oxidation using acyl-CoA oxidase
- Cellular component
- peroxisome;peroxisomal matrix;cytosol
- Molecular function
- 3-hydroxyacyl-CoA dehydrogenase activity;dodecenoyl-CoA delta-isomerase activity;enoyl-CoA hydratase activity;signaling receptor binding;protein binding;long-chain-enoyl-CoA hydratase activity;enzyme binding